Skip navigation
Skip navigation

PCSK9 inhibitors - clinical applications

Schmidli, Robert


The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against PCSK9 and inhibit its activity. Phase II trials have shown alirocumab and evolocumab to be effective at lowering LDL cholesterol. Preliminary results of these phase II trials show...[Show more]

CollectionsANU Research Publications
Date published: 2016-10
Type: Journal article
Source: Australian prescriber
DOI: 10.18773/austprescr.2016.061
Access Rights: Open Access


File Description SizeFormat Image
01 Schmidli R PCSK9 inhibitors clinical 2016.pdf200.1 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator